IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4376
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$5M
John M. Climaco
CNS Pharmaceuticals, Inc. engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$CNSP CNS Pharmaceuticals, Inc. | 32 | 13 | 22 | 47 | - | - | -156.4% | -130.6% | - | - | - | - | 0.0% | 20.0x | $5M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
CNS Pharmaceuticals, Inc. (CNSP) receives a "Avoid" rating with a composite score of 32.0/100. It ranks #4376 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
John M. Climaco
Chief Executive Officer
Labor Force
5
13
24
32
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for CNSP
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CNSP.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -156.4% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 7yr history
Interest coverage -1537.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags CNS Pharmaceuticals, Inc. with an Avoid rating, assigning a composite score of 32.0/100 and 1 out of 5 stars. Ranked #4376 of 7,333 stocks, CNSP falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CNS Pharmaceuticals, Inc. registers a weak quality score of just 13/100, indicating significant profitability challenges. The company reports a return on equity of -156.4% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
CNSP registers a value score of just 22/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.20x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
CNS Pharmaceuticals, Inc.'s investment score of 24/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -130.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CNSP is currently showing below-average momentum at 47/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.94 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
CNSP's stability score of 32/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.94 and a debt-to-equity ratio of 20.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
CNSP carries a short interest score of 61/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 20.00x), micro-cap liquidity risk. At $5M market cap (micro-cap), CNS Pharmaceuticals, Inc. offers reasonable institutional liquidity.
CNS Pharmaceuticals, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4376 of 7,333 overall (40th percentile). Key comparisons include ROE of -156.4% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CNSP currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (13) would have the largest impact on the composite score.
ROE 6207% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 9900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate CNS Pharmaceuticals, Inc. (CNSP) as Avoid with a composite score of 32.0/100 at a current price of $3.01. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (47th percentile) and stability (32th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (13th percentile) and value (22th percentile) tempers our overall conviction. We assign a No Moat rating (19/100), Medium uncertainty, and Poor capital allocation.
Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
CNS Pharmaceuticals, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 32.0/100 places it at rank #4376 in our full 7,333-stock universe. At $5M in market capitalization, CNS Pharmaceuticals, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (47th percentile) are neutral regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for CNS Pharmaceuticals, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $3.01, CNS Pharmaceuticals, Inc. is trading at a premium to fundamental value. Our value factor score of 22/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.2x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (20% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 32.0/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Below-average quality (13th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Medium uncertainty rating to CNS Pharmaceuticals, Inc.. The stock presents a balanced risk profile: below-average price stability (32th percentile) and weak quality scores (13th percentile). While not risk-free, the core business fundamentals are adequate to withstand moderate economic stress, and the range of potential outcomes around our fair value estimate is manageable.
Specific risk factors that inform our assessment include: below-average price stability (32th percentile); weak quality scores (13th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 32th percentile and quality factor at the 13th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (20% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile is favorable for long-term investors.
We rate CNS Pharmaceuticals, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-156.4%), weak asset returns (ROA -130.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — CNS Pharmaceuticals, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, CNS Pharmaceuticals, Inc. receives a Avoid rating with a composite score of 32.0/100 (rank #4376 of 7,333). Our quantitative framework assigns a No Moat (19/100, trend: stable), Medium uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on CNS Pharmaceuticals, Inc. at this time. The combination of limited competitive advantages, medium uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign CNS Pharmaceuticals, Inc. a meaningful economic moat, scoring 19/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and financial resilience (6.3/20). GM N/A vs sector 43%, OM N/A vs sector 1%. Interest coverage -1537.5x. These pillars form the core of CNS Pharmaceuticals, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect CNS Pharmaceuticals, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 13/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -156.4% and ROA of -130.6%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -156.4% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 20%. The sector median D/E is 0%, putting CNS Pharmaceuticals, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. BIOLASE, Inc. (NASDAQ: BIOL) On Jan. 29, Biolase reported full-year 2023 interim revenue of $48.9 million to $49.2 million, up 1% year-over-year compared to the consensus of $49.21 million. The company’s stock fell around 43% over the past five days ...
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales guidance below estimates. UPS reported a fourth-quarter fiscal 2023 revenue decline of 7.8% year-over-year to $24.92 billion, missing the consensus of $25.43 billion. Adjusted EPS was $2.47, down from $3.62 in Q4 2022, in line with the consensus. United Parcel Service shares dipped 8.3% to $145.04 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers Agape ATP Corporation (NASDAQ: ATPC) shares jumped 79% to $0.9120. Pixelworks, Inc. (NASDAQ: PXLW) rose 56.8% to $2.3209 after the company entered into a multi-year agreement with Walt Disney Studios. Agrify Corporation (NASDAQ: AGFY) surged 50.7% to $0.9120 after a 13D filing showed I-Tseng Jenny Chan reported a 49.99% stake in the company. Rail Vision Ltd. (NASDAQ: RVSN) gained 38.8% to $20.38 after the company announced its next generation AI-based computer to be incorporated in its Main Line and Switch Yard systems. Inspire Veterinary Partners, Inc. (NASDAQ: IVP) climbed 38% to $0.2359 after falling around 24% on Monday. Inspire Veterinary Partners recently filed a prospectus related to up to a $5 million public offering. Sanmina Corporation (NASDAQ: SANM) shares climbed 36.7% to $69.21 after the company reported better-than-expected first-quarter financial results and issued second-quarter guidance above estimates. Selina Hospitality PLC (NASDAQ: SLNA) gained 20.8% to $0.4603. C3is Inc. (NASDAQ: CISS) shares surged 19.1% to $0.1609 after a 13G filing showed S.H.N. Financial reported a 9.1% stake in the company. Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) rose 18.2% to $0.39. Kura Oncology, Inc. (NASDAQ: KURA) climbed 16.1% to $21.60. Kura Oncology reported preliminary ziftomenib combination data in acute myeloid leukemia. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 13.9% to $1.56 after gaining more than 25% on ...
Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter. Super Micro Computer reported quarterly earnings of $5.59 per share, beating the analyst consensus estimate of $4.93. The company reported quarterly sales of $3.67 billion, which topped the analyst consensus estimate of $3.06 billion. The company also raised its fiscal year 2024 guidance for revenues from a range of $10 billion to $11 billion to a range of $14.3 billion to $14.7 billion. Super Micro Computer shares jumped 10.6% to $548.25 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Agape ATP Corporation (NASDAQ: ATPC) gained 65.1% to $0.8420 in pre-market trading after gaining around 13% on Monday. Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 45.3% to $1.99 in pre-market trading after gaining more than 25% on Monday. Petros Pharmaceuticals recently announced completion of initial cohort of Phase 2 equivalent self-selection study. C3is Inc. (NASDAQ: CISS) shares jumped 40.6% to $0.19 in pre-market trading after a 13G filing showed ...
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. PCTEL, Inc. (NASDAQ: PCTI) climbed 47.3% to $6.86. On Friday, Amphenol Corp (NYSE: APH) inked a deal to acquire PCTEL for around $139.7 million. Almacenes Éxito S.A. (NYSE: EXTO) shares rose 32.6% to $6.66. MMTec, Inc. (NASDAQ: MTC) surged 30% to $0.7608. Tempest Therapeutics, Inc. (NASDAQ: TPST) gained 29% to $4.72. LQR House Inc. (NASDAQ: LQR) shares climbed 24.5% to $0.2148. LQR House announced that through its custom marketing campaign and strategic efforts, Von Payne Whiskey is now displayed on the shelves of the retail giant, Costco. Secoo Holding Limited (NASDAQ: SECO) rose 23% to $0.7868 after declining 37% on Friday. Ensysce Biosciences, Inc. (NASDAQ: ENSC) climbed 22.2% to $1.76. E2open Parent Holdings, Inc. (NYSE: ETWO) gained 22% to $3.00. Elliott Investment Management L.P. reported a 9% stake in E2open Parent Holdings as of Oct. 13. Inotiv, Inc. (NASDAQ: NOTV) climbed 21.2% to $2.4850. Zapp Electric Vehicles Group Limited (NASDAQ: ZAPP) gained 21.2% to $0.6195. Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) shares jumped 20.8% to $0.5799 after jumping 45% on Friday. Mereo BioPharma Group plc (NASDAQ: MREO) climbed 20% to $1.55. Ultragenyx and Mereo BioPharma announced interim Phase 2 data from Phase 2/3 Orbit study demonstrating setrusumab significantly reduced fracture rates in patients with osteogenesis imperfecta. Prothena Corporation plc (NASDAQ: PRTA) gained 19.7% to $52.78. Alignment Healthcare, Inc. (NASDAQ: ALHC) gained 17.8% to $7.80 after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $9 to $10. Consolidated Communications Holdings, Inc. (NASDAQ: CNSL) surged 17.5% to $4.1493 after the company announced an agreement to be acquired by Searchlight Capital Partners and British Columbia Investment Management. Modular Medical, Inc. (NASDAQ: MODD) gained 17.4% to $1.08. Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 15.5% to $0.39. indie Semiconductor, Inc. (NASDAQ: INDI) climbed 15% to $5.60. indie Semiconductor expects third-quarter revenue ...
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. Timber Pharmaceuticals, Inc. (NYSE: TMBR) gained 97.1% to $2.7993 as the company agreed to be acquired by LEO US Holding, Inc., a wholly-owned subsidiary of LEO Pharma A/S, for a total transaction value of $36 million.. MediaCo Holding Inc. (NASDAQ: MDIA) jumped 38.5% to $0.79. Novo Integrated Sciences, Inc. (NASDAQ: NVOS) gained 39% to $0.1849. Tian Ruixiang Holdings Ltd (NASDAQ: TIRX) shares surged 34.2% to $1.45. Fresh Vine Wine, Inc. (NYSE: VINE) gained 32% to $0.41. China Pharma Holdings, Inc. (NYSE: CPHI) climbed 26.5% to $0.2771. STRATA Skin Sciences, Inc. (NASDAQ: SSKN) surged 24.1% to $0.7829. Genius Group Limited (NYSE: GNS) shares climbed 22.2% to $1.4414 after jumping 19% on Friday. The Growth for Good Acquisition Corporation (NASDAQ: GFGD) shares gained 21.6% to $10.29 in pre-market trading. The Growth for Good Acquisition Corporation announced postponement of its extraordinary general meeting of shareholders and extension of redemption date. Kingstone Companies, Inc. (NASDAQ: KINS) surged 21.3% to $1.65. BioNexus Gene Lab Corp. (NASDAQ: BGLC) gained 21.2% to $1.03. Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) surged 20.4% to $6.41. CVD Equipment Corporation (NASDAQ: CVV) jumped 20% to $6.60. Tupperware Brands Corporation (NYSE: TUP) surged 18% to $2.9194. Applied Optoelectronics, Inc. (NASDAQ: AAOI) climbed 18% to $15.11. Applied Optoelectronics Form 4 Filing showed President and CEO Lin Chih-Hsiang (Thompson) bought 20,000 shares at an average price of $12.38/share. BTC Digital Ltd. (NASDAQ: METX) gained 17.3% to $0.1994. VinFast Auto Ltd. (NASDAQ: VFS) ...